Neurocrine Biosciences, Inc. (NBIX) has a consensus analyst rating of Buy, based on 36 analysts covering the stock. Of those, 31 recommend buying, 5 recommend holding, and 0 recommend selling.
The analyst consensus price target for NBIX is $173.67, representing a +32.8% upside from the current price of $130.81. Price targets range from a low of $140.00 to a high of $220.00.
